PDS 전략 업데이트 및 2023년 재무 결과
즉각적인 석방
NetScientific PLC
Portfolio company PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results
· Unique mechanism of action of the combination of PDS01ADC and Versamune® results in 3-year survival of 75% and 75% overall response rate in advanced head and neck cancer trial
· As a result, Company to focus late-stage clinical strategy on triple combination of PDS01ADC, PDS0101 (Versamune® HPV) and KEYTRUDA® in advanced head and neck cancer
· Strong safety profile of IL-12 fused antibody drug conjugate (PDS01ADC) demonstrated to date with data generated in >300 cancer patients; Versamune® HPV tested in >110 HNSCC patients
· Successful recent meeting with FDA provided clear guidance on trial design and regulatory pathway for pivotal randomised trial of triple combination in recurrent metastatic HPV-positive HNSCC
NetScientific Plc (AIM: NSCI), the deep tech and life sciences VC investment group, reports that its portfolio company PDS Biotechnology Corporation (Nasdaq: PDSB), in which it holds a 3.5% direct holding, a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced an update to its clinical development strategy and reported its financial results for the year ended December 31, 2023. Extracts of the announcement are below.
PDS Biotech의 CEO인 Frank Bedu-Addo 박사는 다음과 같이 말했습니다.
"We have obtained compelling data from several Phase 2 trials in the fourth quarter of 2023, including long-term survival data from the National Cancer Institute (NCI)-led triple combination trial of PDS01ADC in combination with Versamune® HPV (PDS0101) and an investigational immune checkpoint inhibitor (ICI), as well as our VERSATILE-002 study. We now have a better understanding of how our drug platform technology works in advanced cancer, and we have therefore made the strategic, data-driven decision to add our novel, investigational IL-12 fused antibody drug conjugate, PDS01ADC, to the promising combination of Versamune® HPV and KEYTRUDA® to advance the triple combination as our top clinical development priority."
그는 계속 :
"By initially addressing the rapidly growing unmet medical need in recurrent metastatic HPV+ head and neck squamous cell cancer (HNSCC), we strongly believe this approach may rapidly establish our proprietary combination of PDS01ADC and Versamune® HPV as a transformative oncology treatment. The data suggest that the triple combination may result in a significant improvement in overall survival rates for patients who currently lack an effective treatment option. It may also significantly increase the rates of durable tumour shrinkage or overall responses. We are grateful to the patients and physicians who participated in the clinical trials which have helped inform our understanding of how the drug therapies may be used most effectively to safely address advanced cancer, and our decision to prioritise the triple combination."
With the recent long-term survival Phase 2 data from the NCI-led triple combination trial, together with favourable safety and extended survival results seen in both ICI naïve and resistant patients in our VERSATILE-002 trial, PDS Biotech has decided to prioritise the triple combination in place of the VERSATILE-003 trial. This decision enables PDS Biotech to focus its resources on the drug regimen it believes has the highest potential to benefit patients with HNSCC and to drive shareholder value.
Kirk V. Shepard, M.D., Chief Medical Officer of PDS Biotech said:
"We have had several discussions with key opinion leaders in HNSCC regarding the use of the triple combination in HNSCC. A clear unmet need is seen in HPV+ HNSCC with few agents being studied in this population due to the difficulty in treating advanced HNSCC. These discussions with expert HNSCC oncologists have guided our decision to prioritise the triple combination in our efforts to address the growing incidence of advanced HPV+ HNSCC."
Katharine A. Price, M.D., Associate Professor of Oncology, Head and Neck Disease Group, Mayo Clinic Comprehensive Cancer Centre, and Principal Investigator of PDS Biotech's upcoming triple combination trial added:
"Despite good outcomes in many patients with HPV-related HNSCC, approximately 20% of patients will develop recurrent, incurable disease, often in young individuals in the prime of their lives. HPV-related HNSCC that progresses after standard first-line chemotherapy is a devastating, hard-to-treat cancer with no HPV-related treatment currently approved. The NCI clinical trial data show significant promise in the use of PDS01ADC in combination with Versamune® HPV. A controlled randomised clinical trial that builds upon the current data is warranted, and I am intrigued by the potential of this unique combination to treat HNSCC."
Clinical Strategy Update:
Triple Combination Clinical Trial (PDS01ADC, Versamune® HPV and KEYTRUDA®)
· Company in discussions with the U.S. Food and Drug Administration (FDA) on the design of potentially pivotal clinical trial to treat HPV+ HNSCC, with the trial expected to start in 2024.
· Previously announced data from Phase 2 NCI-led triple combination clinical trial for the treatment of recurrent/metastatic ICI naïve and ICI resistant HPV16-positive cancers including head and neck, anal, cervical, vaginal, and vulvar cancers support rationale:
o ICI naïve group:
· 75% of patients remain alive at 36 months. The median overall survival (OS) was not reached. Published results show a 36-month survival rate of approximately 20% with ICIs. An overall response rate (ORR) of 75% and complete response of 38% were seen in patients treated with the triple combination. Published ORR of <40% seen with immunotherapeutic agents.
o ICI resistant group:
· 12-month OS rate of 72%, and 63% ORR in patients with optimal dose of PDS01ADC. Median OS approximately 20 months; published 12-month OS rate in HPV-positive ICI-resistant cancer is ~30%; published median OS in HPV-positive ICI-resistant cancer is 3.4 months.
o 모든 HPV 양성 종양 유형에서 반응이 나타났습니다.
리더십 임명
· In January 2024, announced the appointment of Dr. Shepard as Chief Medical Officer.
· In November 2023, announced the appointment of Lars Boesgaard as Chief Financial Officer.
2023 년도 전체 실적
Net loss for the year ended December 31, 2023, was approximately $42.9 million, or $1.39 per basic and diluted share, compared to a net loss of $40.9 million, or $1.43 per basic share and diluted share, for the year ended December 31, 2022. The higher net loss was primarily the result of increased operating loss and increased net interest expense.
Research and development expenses for the year ended December 31, 2023, decreased to $27.8 million, compared to $29.4 million for the year ended December 31, 2022. The decrease of $1.7 million was primarily attributable to the $10 million purchase of the rights to PDS01ADC in 2022, partially offset by an increase in clinical costs of $6.1 million and an increase in personnel costs of $2.1 million.
General and administrative expenses for the year ended December 31, 2023, increased to $15.3 million compared to $12.2 million for the year ended December 31, 2022. The $3.1 million increase was primarily attributable to an increase in personnel costs of $1.5 million and an increase in professional fees of $1.6 million.
Total operating expenses for the year ended December 31, 2023, were $43.0 million, an increase of approximately 3.3% compared to $41.7 million total operating expenses for the year ended December 31, 2022.
Net interest expense increased to $1.3 million for the year ended December 31, 2023, compared to $0.4 million for the year ended December 31, 2022. The change was due to higher interest expense related to the Company's notes payable, partially offset by higher interest income on bank deposits.
During the fourth quarter of 2023, the Company raised approximately $10.5 million in net proceeds from its "at-the-market" sales agreement.
The Company's cash balance as of December 31, 2023, was $56.6 million.
PDS Biotech 발표의 전체 버전은 여기에서 액세스할 수 있습니다.
https://pdsbiotech.com/index.php/investors/news-center/press-releases/press-releases1/131-2024-news/902-iotechnnounceslinicaltrategypdateandeports20240327
-Ends-
자세한 내용은 문의하시기 바랍니다 :
넷사이언티픽 | |
CEO 일리안 일리예프 | 벨베데레 커뮤니케이션즈를 통해 |
| |
Panmure Gordon(UK) Limited(NOMAD 및 Broker) |
|
엠마 얼 / 프레디 크로슬리 / 윌 구드 / 마크 로저스(기업 금융) Rupert Dearden(기업 중개) | +44 (0)20 7886 2500 |
벨베데레 커뮤니케이션즈 존 웨스트 / 루 앵거스 / 릴리 피어스 |
+44 (0)20 7653 8702 |
NetScientific 소개
NetScientific plc(AIM: NSCI)는 혁신적인 기업으로 구성된 국제 포트폴리오를 갖춘 심층 기술 및 생명 과학 VC 투자 그룹입니다.
NetScientific은 영국 및 국제적으로 고성장 기업을 식별, 투자 및 구축합니다. 회사는 포트폴리오의 적극적인 관리, 핵심 가치 변곡점 진행, 부분 또는 전체 유동성 이벤트를 통한 투자 수익 제공을 통해 가치를 추가합니다.
NetScientific은 자본 효율적인 투자 접근 방식을 채택하고, 대차대조표를 사법적으로 활용하고, 전액 출자한 VC 자회사인 EMV Capital을 통해 투자를 신디케이트함으로써 차별화됩니다. 그룹은 회사 포트폴리오에 대한 직접 지분과 보유 지분을 혼합하여 확보하여 대규모 포트폴리오를 지원할 수 있는 린 구조를 만듭니다.
NetScientific은 영국 런던에 본사를 두고 있으며 런던 증권 거래소에서 운영하는 시장인 AIM에서 거래할 수 있습니다.
www.netscientific.net
피디에스바이오테크놀로지 소개
PDS Biotechnology is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines. The Company plans to initiate a pivotal clinical trial in 2024 to advance its lead program in advanced head and neck squamous cell cancers (HNSCC). PDS Biotech's lead program is a proprietary dual-acting combination of antibody drug conjugate (ADC) PDS01ADC and T-cell activator Versamune® HPV in regimen with a standard-of-care immune checkpoint inhibitor. Proof-of-concept long-term data have shown positive survival results and tumor shrinkage with this combination and indicate favorable tolerability.
With a novel investigational "inside-out" mechanism, the dual immunotherapy has shown compelling results with potential to successfully disrupt a tumor's inside defenses, while also generating potent, targeted killer T-cells to attack the tumor from the outside. Robust data from more than 350 patients, as well as ongoing clinical trials across multiple tumor types and standard treatment regimens, have validated the platforms and point to potential broad utility.
Our Infectimune® based vaccines have demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T-cell responses, including long-lasting memory T-cell responses in pre-clinical studies to date.
www.pdsbiotech.com
RNS는 귀하의 IP 주소를 사용하여 약관 준수 여부를 확인하고, 귀하가 이 커뮤니케이션에 포함된 정보를 사용하는 방식을 분석하고, 그러한 분석을 익명으로 다른 사람과 상용 서비스의 일부로 공유할 수 있습니다. RNS와 런던 증권 거래소가 귀하가 제공한 개인 데이터를 사용하는 방법에 대한 자세한 내용은 개인 정보 보호 정책을 참조하십시오.